Western Blot: PPAR gamma/NR1C3 Antibody [NBP2-22106] - Total protein from 3T3-L1 mouse embryonic fibroblast adipose-like cell line, separated by 4-12% SDS-PAGE, transferred to nitrocellulose membrane and blocked in 5% ...read more
Immunohistochemistry-Paraffin: PPAR gamma Antibody [NBP2-22106] - IHC analysis of PPAR gamma in mouse liver.
Western Blot: PPAR gamma Antibody [NBP2-22106] - Western blot analysis of PPAR gamma in 1. human adipose and 2. human adrenal lysate.
This PPAR gamma antibody is useful for Immunohistochemistry paraffin embedded sections and Western blot, where a band is detected at ~55 kDa. Prior to immunostaining paraffin tissues, antigen retrieval with sodium citrate buffer (pH 6.0) is recommended. The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.Use in immunoprecipitation reported in scientific literature (PMID: 27862692).
55 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Peroxisome proliferator-activated receptor gamma (PPARG), also known as nuclear receptor subfamily 1 group C member 3, NR1C3, GLM1, CIMT1, PPARG1, PPARG2, and PPARgamma, regulates adipocyte differentiation and binds peroxisome proliferators that include hypolipidemic drugs and fatty acids. PPARG regulates the peroxisomal beta-oxidation pathway of these fatty acids. PPARG activates transcription for acyl-CoA oxidase and regulates glucose homeostasis. PPARG is a member of the PPAR family, which is a subfamily of nuclear receptors. PPARG is found in the nucleus and the cytoplasm and is most prevalent in adipose tissue but also found in skeletal muscle, spleen, heart, liver, placenta, lung, and ovary. PPARG is found in three known isoforms (57.6, 54.8, and 21.6 kDa), which are produced by alternative splicing. The PPARG protein is subject to phosphorylation. PPARG has been linked to many diseases such as obesity, diabetes, atherosclerosis, and cancer. Recent research has indicated that mutations in PPARG play a role in non-alcoholic fatty liver disease (PMID: 22160635). Other research has found that using PPARG ligands as part of a chemotherapy treatment could help improve treatment for advanced pancreatic cancer (PMID: 22020928). Similar cancer research discovered that PPARG can be used to induce colorectal carcinoma cell death, making PPARG, in conjunction with survivin and caspase-3, a potential cancer cell regulator (PMID: 21765467).
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Mouse small intestine was homogenised and protein content was quantified by a BCA assay. Twenty micrograms of protein were resolved on a 4-12% Bis-Tris gel and transferred to nitrocellulose membranes. Membranes were probed with primary antibody PPAR gamma diluted 1:1000 in 5% BSA 2, before incubation with Anti-rabbit secondary horseradish peroxidase-conjugated antibody 1:5000. Blots were visualised with Immobilon Western Chemiluminescence HRP Substrate and imaged with Syngene chemiluminescence imaging system.
3T3-L1 mouse embryonic fibroblast adipose-like cell line
Western Blot: PPAR gamma/NR1C3 Antibody [NBP2-422106SS] - Total protein from 3T3-L1 mouse embryonic fibroblast adipose-like cell line, separated on a 4-12% gel by SDS-PAGE, transferred to nitrocellulose membrane and blocked in 5% non-fat milk for 1h at room temperature. The membrane was probed with anti-PPAR gamma 1:800 in non-fat milk.
Product General Protocols
View specific protocols for PPAR gamma/NR1C3 Antibody (NBP2-22106):
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.